The successful outcome of the CHAPTER-1 Phase 2 clinical study is a significant milestone for Pharvaris, likely leading to increased investor confidence and a positive perception of the company's future prospects. This news directly impacts the company's valuation as it progresses towards potential commercialization of its product, which is why the stock is expected to experience upward movement in the short term.